Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Tumor Necrosis Factor Alpha (TNF-a) Blockade and Risk of Lymphoma: Systematic Review and Analysis of Literature

Jeyanthi Ramanarayanan, Shalu Pahuja, Myron S Czuczman, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2008) 112 (11): 5278.

https://doi.org/10.1182/blood.V112.11.5278.5278

Published: 2008

Journal Articles

Efficacy and Safety of Rituximab in Post Transplant Lymphoproliferative Disorders (PTLD): Pooled Analysis and Review of Literature.

Jeyanthi Ramanarayanan, MD, Ganapathy S. Krishnan, MD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2007) 110 (11): 1084.

https://doi.org/10.1182/blood.V110.11.1084.1084

Published: 2007

Journal Articles

Effect of Renin Angiotensin System (RAS) Blockade on Hematological Parameters in Patients with Secondary Polycythemia (SP) Associated with Chronic Obstructive Pulmonary Disease (COPD) and Sleep Apnea (SA).

Jeyanthi Ramanarayanan, MD, Frank Brodzik, MPAS, Syed Mehdi, MD, Donald Pasquale, MD

Blood (2006) 108 (11): 3759.

https://doi.org/10.1182/blood.V108.11.3759.3759

Published: 2006

Journal Articles

Efficacy and Safety of Rituximab in the Treatment of Refractory/Relapsed Idiopathic Thrombocytopenic Purpura (ITP): Results of a Meta-Analysis of 299 Patients.

Jeyanthi Ramanarayanan, MD, Frank Brodzik, MPAS, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2006) 108 (11): 1076.

https://doi.org/10.1182/blood.V108.11.1076.1076

Published: 2006

Journal Articles

Individualized Dosing of Fludarabine (FLU) for Low Grade Lymphoproliferative Disorders Results in Administration of Less Medication with Fewer Infections and Equivalent Survival.

Donald Pasquale, MD, Nalini Ramanathan, MD, Sarah L. Scarpace, Pharm.D., Hung Nguyen, Amy I. Jackson, Jeyanthi Ramanarayanan, MD

Blood (2006) 108 (11): 4977.

https://doi.org/10.1182/blood.V108.11.4977.4977

Published: 2006

Journal Articles

Autoimmune Disease (AD) in Patients with Myelodysplastic Syndrome (MDS): A Retrospective Single Institution Study.

Jeyanthi Ramanarayanan, MD, Alan N. Baer, MD, Minoo Battiwalla, MD, Laurie A. Ford, Meir Wetzler, MD, Maria R. Baer, MD.

Blood (2004) 104 (11): 4736.

https://doi.org/10.1182/blood.V104.11.4736.4736

Published: 2004

Journal Articles

In Vivo Downregulation of Bcl-2 by G3139 (G) Enhances Rituximab (R) Anti-Tumor Activity: Effect of Sequential Versus Concurrent G3139 Administration on Survival in a Lymphoma-Bearing SCID Mouse Model.

Jeyanthi Ramanarayanan, MD, Francisco J. Hernandez-Ilizaliturri, MD, Myron S. Czuczman, MD.

Blood (2004) 104 (11): 1398.

https://doi.org/10.1182/blood.V104.11.1398.1398

Published: 2004

NARROW

Tumor Necrosis Factor Alpha (TNF-a) Blockade and Risk of Lymphoma: Systematic Review and Analysis of Literature

Efficacy and Safety of Rituximab in Post Transplant Lymphoproliferative Disorders (PTLD): Pooled Analysis and Review of Literature.

Effect of Renin Angiotensin System (RAS) Blockade on Hematological Parameters in Patients with Secondary Polycythemia (SP) Associated with Chronic Obstructive Pulmonary Disease (COPD) and Sleep Apnea (SA).

Efficacy and Safety of Rituximab in the Treatment of Refractory/Relapsed Idiopathic Thrombocytopenic Purpura (ITP): Results of a Meta-Analysis of 299 Patients.

Individualized Dosing of Fludarabine (FLU) for Low Grade Lymphoproliferative Disorders Results in Administration of Less Medication with Fewer Infections and Equivalent Survival.

Autoimmune Disease (AD) in Patients with Myelodysplastic Syndrome (MDS): A Retrospective Single Institution Study.

In Vivo Downregulation of Bcl-2 by G3139 (G) Enhances Rituximab (R) Anti-Tumor Activity: Effect of Sequential Versus Concurrent G3139 Administration on Survival in a Lymphoma-Bearing SCID Mouse Model.

Email alerts

ASH Publications

American Society of Hematology

Tumor Necrosis Factor Alpha (TNF-a) Blockade and Risk of Lymphoma: Systematic Review and Analysis of Literature

Efficacy and Safety of Rituximab in Post Transplant Lymphoproliferative Disorders (PTLD): Pooled Analysis and Review of Literature.

Effect of Renin Angiotensin System (RAS) Blockade on Hematological Parameters in Patients with Secondary Polycythemia (SP) Associated with Chronic Obstructive Pulmonary Disease (COPD) and Sleep Apnea (SA).

Efficacy and Safety of Rituximab in the Treatment of Refractory/Relapsed Idiopathic Thrombocytopenic Purpura (ITP): Results of a Meta-Analysis of 299 Patients.

Individualized Dosing of Fludarabine (FLU) for Low Grade Lymphoproliferative Disorders Results in Administration of Less Medication with Fewer Infections and Equivalent Survival.

Autoimmune Disease (AD) in Patients with Myelodysplastic Syndrome (MDS): A Retrospective Single Institution Study.

In Vivo Downregulation of Bcl-2 by G3139 (G) Enhances Rituximab (R) Anti-Tumor Activity: Effect of Sequential Versus Concurrent G3139 Administration on Survival in a Lymphoma-Bearing SCID Mouse Model.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only